Antibodies to a new viral citrullinated peptide, VCP2: Fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies

Clinical and Experimental Immunology

Volumn 164, Issue 3, 2011, Pages 337-345

  Pratesi, F ^a   Tommasi, C ^a   Anzilotti, C ^a   Puxeddu, I ^a   Sardano, E ^a   Di Colo, G ^a   Migliorini, P ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b Toscana Biomarkers Srl   (Italy)

Author keywords

Antibody specificity; Autoantibodies; Cyclic citrullinated peptide; Epstein Barr virus; Rheumatoid arthritis

Indexed keywords

ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; VIRAL CITRULLINATED PEPTIDE 2; VIRUS PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CITRULLINE; COMPUTATIONAL BIOLOGY; EPITOPE MAPPING; EPITOPES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; VIRAL PROTEINS;

EID: 79955424299     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04378.x     Document Type: Article

References (36)

1. Vander Cruyssen B, Peene I, Cantaert T etal. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 2005; 4:468-74.
2. Uysal H, Nandakumar KS, Kessel C etal. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 2010; 233:9-33.
3. Girbal-Neuhauser E, Durieux JJ, Arnaud M etal. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999; 162:585-94.
4. Sebbag M, Moinard N, Auger I etal. Epitopes of human fibrin recognised by the rheumatoid arthritis specific autoantibodies to citrullinated proteins. Eur J Immunol 2006; 36:2250-63.
5. Schellekens GA, de Jong BA, van den Hoogen FH, Van de Putte LB, Van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-81.
6. Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 2006; 33:647-51.
7. van de Stadt LA, van der Horst AR, de Koning MH etal. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011; 70:128-33.
8. Ioan-Facsinay A, El-Bannoudi H, Scherer HU etal. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 2011; 70:188-93.
9. Arnett FR, Edworthy SM, Bloch DA, Mc Shane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-2.
10. Stolt P, Bengtsson C, Nordmark B Lindblad S, Lundberg I, Klareskog L, Alfredsson L, EIRA Study Group. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population-based case-control study, using incident cases. Ann Rheum Dis 2003; 62:835-41.
11. Mahdi H, Fisher BA, Källberg H etal. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009; 41:1319-24.
12. Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985; 24:242-9.
13. Vasey FB, Espinoza LR. Psoriatic arthropathy. In: Calin A, ed. Spondyloarthropathies. Orlando: Grune & Stratton, Inc., 1984:151-85.
14. Tan EM, Cohen AS, Fries JP etal. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
16. Meltzer M, Franklin EC, Elias K, McKluskey RT, Cooper N. Cryoglobulinemia. A clinical and laboratory study: cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40:837-56.
17. Vitali C, Bombardieri S, Jonsson R etal. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-8.
18. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 1963; 85:2149-53.
19. Atherton E, Sheppard RC. Solid phase peptide synthesis: a practical approach. Oxford: IRL Press, 1989.
20. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988; 85:5409-13.
21. Anzilotti C, Riente L, Pratesi F etal. IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders. Rheumatology 2007; 46:1579-82.
22. Kinloch A, Tatzer V, Wait R etal. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R1421-9.
23. Sauter M, Mueller-Lantzsch N. Characterization of an Epstein-Barr virus nuclear antigen 2 variant (EBNA 2B) by specific sera. Virus Res 1987; 8:141-52.
24. Hazelton RA, Sculley TB, Pope JH. The prevalence of antibodies to an Epstein-Barr virus-induced polypeptide (EBNA 2) in the sera of rheumatoid arthritic families. Br J Rheumatol 1987; 26:193-6.
25. Quinn MA, Gough AK, Green MJ etal. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxf) 2006; 45:478-80.
26. Forslind K, Ahlmén M, Eberhardt K, Hafstrom I, Svensson B, BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63:1090-5.
27. Nielen MM, van der Horst AR, van Schaardenburg D etal. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005; 64:1199-204.
28. van der Linden MP, van der Woude D, Ioan-Facsinay A etal. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60:2232-41.
29. Syversen SW, Goll GL, van der Heijde D etal. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69:345-51.
30. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010; 12:203.
31. Snir O, Widhe M, von Spee C etal. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009; 68:736-43.
32. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA etal. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006; 54:3799-808.
33. Svärd A, Kastbom A, Reckner-Olsson A, Skogh T. Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther 2008; 10:R75.
34. Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine 2007; 74:418-26.
35. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54:733-41.
36. Joseph AM, Babcock GJ, Thorley-Lawson DA. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 2000; 74:9964-71.